Asthma control

The European Commission has approved Dupixent ( Dupilumab ) for use in adults and adolescents 12 years and older as...


Dupilumab ( Dupixent ), a fully human VelocImmune-derived anti-interleukin-4 ( IL-4 ) receptor alpha monoclonal antibody, inhibits signaling of IL-4...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


FDA ( U.S. Food and Drug Administration ) has approved Inbrija ( Levodopa inhalation powder ) for intermittent treatment...



Asthma exacerbations are commonly precipitated by viral upper respiratory infections ( URIs ). Vitamin D insufficiency associates with susceptibility to...


The role of Tiotropium ( Spiriva ) for the treatment of adolescents with asthma has not yet been clearly defined....


In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic...


Additional results from an interim analysis of a pivotal phase 2b study of Dupilumab in adult patients with moderate-to-severe asthma...


The maturation, recruitment and survival of eosinophils in the respiratory tract are determined by IL-3, GM-CSF, but especially by IL-5,...


Bronchial thermoplasty is a procedure that consists of the delivery of controlled radiofrequency-generated heat via a catheter inserted into the...


In mild asthma exercise-induced bronchoconstriction is usually treated with inhaled short-acting beta2-agonists ( SABAs ) on demand. The hypothesis was that...


Although yoga is frequently used by patients with asthma, its efficacy in alleviating asthma remains unclear. A study has systematically assessed...


In patients with symptomatic asthma receiving ICS or ICS+LABA, phase III studies have demonstrated improved lung function with Tiotropium (...


Once-daily Tiotropium ( Spiriva ) Respimat, a long-acting anticholinergic bronchodilator, has been shown in a phase III program to improve...


Data from phase 3 studies of Tiotropium ( Spiriva ) delivered via the Respimat inhaler in mild, moderate and severe...


Omalizumab ( Xolair ) has been recommended as an add-on option for the treatment of patients with moderate-severe allergic asthma...


Acute exacerbations of chronic obstructive pulmonary disease ( COPD ) are a major cause of hospital admission and mortality. They...


Results published in the New England Journal of Medicine ( NEJM ) and presented at the European Respiratory Society (...


Adult-onset asthma and chronic obstructive pulmonary disease ( COPD ) are major public health burdens. This review presents a comprehensive...